Skye Bioscience Inc (SKYE)

[shakeshack]

Performing the study in Australia make a difference?

From their presentation:

Australia offers centers of
excellence with a pool of
qualifying patients as well
as economic incentives
that when leveraged, could
possibly lead to expedited
enrollments and quality
data
• Nemus has identified an
API synthesis partner in
AMRI which has expertise
in cannabinoid
manufacturing, scale-up
capability, and a global
footprint

Perform Phase 1b/2a
clinical studies in
patients utilizing sites in
Australia to generate
safety, efficacy, and
pharmacokinetic data